Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Relmada Therapeutics, Inc. is one of them.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company that develops innovative therapies for oncology and central nervous system disorders. In 2025, the company will expand its pipeline with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compulsivity disorders such as Prader-Willi Syndrome (PWS).

In September 2025, Relmada Therapeutics, Inc. (NASDAQ:RLMD) reported promising Phase 2 results for NDV-01, a sustained-release formulation of gemcitabine and docetaxel, showing a 91% complete response rate. The firm is preparing to launch a Phase 3 registrational trial in early 2026. Sepranolone is also progressing toward a Phase 2 trial for PWS, with regulatory and manufacturing steps underway. Additionally, the business regained compliance with Nasdaq’s minimum bid price requirement, ensuring continued listing and signaling market stability, placing it among the best penny stocks to watch in biotech.

On the financial side, Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted a $9.9 million net loss in Q2 2025 and held approximately $20.6 million in cash, reflecting a cautious cash position as it ramps up for larger clinical trials.

While we acknowledge the potential of RLMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.